SUBCLINICAL AKI AND CLINICAL OUTCOMES IN ELDERLY PATIENTS UNDERGOING CARDIAC SURGERY: DIAGNOSTIC UTILITY OF NGAL VERSUS STANDARD CREATININE INCREASE CRITERIA
Abstract
Background: AKI is a common and serious postoperative complication in patients undergoing cardiac surgery and its incidence is particularly high among elderly patients. Cardiac surgery-associated AKI (CSA-AKI) represents the second most common cause of AKI in the intensive care unit but its true incidence could be underestimated, especially in elderly population. The current biomarkers of AKI are unreliable and delayed during acute changes in kidney function. In the setting of subclinical AKI (SAKI), biomarkers of tubular damage such as NGAL, seems to be an early indicator of kidney damage. The aim of this study was to investigate NGAL utility in the SAKI diagnosis on the first 48 hours after cardiac surgery and its helpfulness in predicting adverse clinical outcomes in comparison to current criteria for AKI.
Methods: This is an observational study of 72 patients admitted to San Bortolo’s cardiac surgery department for elective cardiosurgical procedure enrolled over a 5-months period. All patients underwent peripheral venous sample 48 hours after cardiac surgery to assess plasmatic Creatinine (48Cr) and NGAL (48pNGAL) in addition to exams already foreseen by clinical practice. For each patient we studied renal, respiratory and cardiovascular outcome during hospitalization as well as 30 days and 6 months mortality. Creatinine Increase AKI (CrIAKI) was defined by 48CrI≥0.3mg/dL and Subclinical Acute kidney Injury (SAKI) was defined by 48pNGAL≥100pg/dL. We also assessed Respiratory (ArespO) as well as Cardiovascular (ACvO ) outcome.
Results: 30 days mortality was 8.3% (6 patients) and 6 months mortality was 12.5% (9 patients). A total of 27 patients (37.5%) presented AKI according to KDIGO (4) and 4 (5.5%) needed RRT. SAKI was significantly associated with 30 days mortality (p=0.0238), six months mortality (p=0.002), Adverse renal outcome ARenO (p=0.004) and need for RRT (p=0.005). CrIAKI was significantly associated with 30 days mortality (p=0.009) and ARenO (p=0.0001), but not with six months mortality nor need for RRT.
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)